In fact, only one trial evaluated the dose-limiting toxicity of the anti-IL-6R monoclonal antibody tocilizumab in combination with trastuzumab and pertuzumab in subjects with metastatic HER2-positive breast cancer. This evidence concerns the gene IL6R and breast carcinoma.